MA49754B1 - Méthodes de traitement de symptômes de gastroparésie au moyen de velusetrag - Google Patents
Méthodes de traitement de symptômes de gastroparésie au moyen de velusetragInfo
- Publication number
- MA49754B1 MA49754B1 MA49754A MA49754A MA49754B1 MA 49754 B1 MA49754 B1 MA 49754B1 MA 49754 A MA49754 A MA 49754A MA 49754 A MA49754 A MA 49754A MA 49754 B1 MA49754 B1 MA 49754B1
- Authority
- MA
- Morocco
- Prior art keywords
- day
- velusetrag
- methods
- treating gastroparesis
- symptoms
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La présente invention concerne des méthodes et des compositions pharmaceutiques pour le traitement de tous les symptômes de la gastroparésie chez un patient humain, la méthode comprenant l'administration au patient humain d'environ 0,5 mg/jour à environ 30 mg/jour, environ 0,5 mg/jour à environ 15 mg/jour, environ 0,5 mg/jour à environ 5 mg/jour, ou environ 5 mg/jour, de velusetrag ou d'un sel pharmaceutiquement acceptable de celui-ci.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762539229P | 2017-07-31 | 2017-07-31 | |
| EP18756041.2A EP3661518B1 (fr) | 2017-07-31 | 2018-07-30 | Méthodes de traitement de symptômes de gastroparésie au moyen de velusetrag |
| PCT/US2018/044337 WO2019027881A1 (fr) | 2017-07-31 | 2018-07-30 | Méthodes de traitement de symptômes de gastroparésie au moyen de velusetrag |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA49754A MA49754A (fr) | 2020-06-10 |
| MA49754B1 true MA49754B1 (fr) | 2024-10-31 |
Family
ID=63245036
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA49754A MA49754B1 (fr) | 2017-07-31 | 2018-07-30 | Méthodes de traitement de symptômes de gastroparésie au moyen de velusetrag |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US11642339B2 (fr) |
| EP (1) | EP3661518B1 (fr) |
| JP (2) | JP7431721B2 (fr) |
| KR (1) | KR102692887B1 (fr) |
| CN (1) | CN110996961A (fr) |
| AU (1) | AU2018309667B2 (fr) |
| BR (1) | BR112020000482A2 (fr) |
| CA (1) | CA3069989A1 (fr) |
| CL (1) | CL2019003598A1 (fr) |
| DK (1) | DK3661518T3 (fr) |
| EA (1) | EA202090416A1 (fr) |
| ES (1) | ES2991549T3 (fr) |
| FI (1) | FI3661518T3 (fr) |
| HR (1) | HRP20241359T1 (fr) |
| HU (1) | HUE068595T2 (fr) |
| IL (1) | IL272023B2 (fr) |
| LT (1) | LT3661518T (fr) |
| MA (1) | MA49754B1 (fr) |
| MD (1) | MD3661518T2 (fr) |
| MX (1) | MX2020001217A (fr) |
| PL (1) | PL3661518T3 (fr) |
| PT (1) | PT3661518T (fr) |
| RS (1) | RS66049B1 (fr) |
| SG (1) | SG11201912266QA (fr) |
| SI (1) | SI3661518T1 (fr) |
| SM (1) | SMT202400447T1 (fr) |
| TW (1) | TW201909896A (fr) |
| UA (1) | UA125596C2 (fr) |
| WO (1) | WO2019027881A1 (fr) |
| ZA (1) | ZA201908495B (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2023346889A1 (en) | 2022-09-20 | 2025-02-20 | Alfasigma S.P.A. | Velusetrag for use in the treatment of chronic intestinal pseudo-obstruction (cipo) |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI351282B (en) | 2004-04-07 | 2011-11-01 | Theravance Inc | Quinolinone-carboxamide compounds as 5-ht4 recepto |
| US7728006B2 (en) | 2004-04-07 | 2010-06-01 | Theravance, Inc. | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists |
| US8309575B2 (en) | 2004-04-07 | 2012-11-13 | Theravance, Inc. | Quinolinone-carboxamide compounds as 5-HT4 receptor agonists |
| TWI377206B (en) * | 2005-04-06 | 2012-11-21 | Theravance Inc | Crystalline form of a quinolinone-carboxamide compound |
| MX2008010555A (es) | 2006-02-16 | 2008-09-15 | Theravance Inc | Proceso para preparar intermediarios de compuestos agonistas de receptor de 5-ht4. |
| HUE038141T2 (hu) | 2009-04-13 | 2018-10-29 | Theravance Biopharma R&D Ip Llc | 5-HT4 receptor agonisták és acetilkolinészteráz inhibitorok kombinációi kognitív rendellenességek kezelésére |
| EP2744493A1 (fr) * | 2011-08-18 | 2014-06-25 | Shire AG | Combinaisons d'un agoniste de récepteur 5-ht4 et d'un inhibiteur de pde4 pour utilisation en thérapie |
| PL2747561T3 (pl) * | 2011-08-25 | 2018-11-30 | Evoke Pharma, Inc. | Leczenie objawów związanych z gastroparezą u osobników płci żeńskiej |
-
2018
- 2018-07-30 SG SG11201912266QA patent/SG11201912266QA/en unknown
- 2018-07-30 SM SM20240447T patent/SMT202400447T1/it unknown
- 2018-07-30 JP JP2020505338A patent/JP7431721B2/ja active Active
- 2018-07-30 BR BR112020000482-0A patent/BR112020000482A2/pt not_active Application Discontinuation
- 2018-07-30 MX MX2020001217A patent/MX2020001217A/es unknown
- 2018-07-30 PL PL18756041.2T patent/PL3661518T3/pl unknown
- 2018-07-30 SI SI201831158T patent/SI3661518T1/sl unknown
- 2018-07-30 US US16/048,933 patent/US11642339B2/en active Active
- 2018-07-30 LT LTEPPCT/US2018/044337T patent/LT3661518T/lt unknown
- 2018-07-30 KR KR1020207005532A patent/KR102692887B1/ko active Active
- 2018-07-30 UA UAA202001354A patent/UA125596C2/uk unknown
- 2018-07-30 FI FIEP18756041.2T patent/FI3661518T3/fi active
- 2018-07-30 CN CN201880047606.7A patent/CN110996961A/zh active Pending
- 2018-07-30 HU HUE18756041A patent/HUE068595T2/hu unknown
- 2018-07-30 PT PT187560412T patent/PT3661518T/pt unknown
- 2018-07-30 DK DK18756041.2T patent/DK3661518T3/da active
- 2018-07-30 MA MA49754A patent/MA49754B1/fr unknown
- 2018-07-30 RS RS20241118A patent/RS66049B1/sr unknown
- 2018-07-30 CA CA3069989A patent/CA3069989A1/fr active Pending
- 2018-07-30 ES ES18756041T patent/ES2991549T3/es active Active
- 2018-07-30 EA EA202090416A patent/EA202090416A1/ru unknown
- 2018-07-30 WO PCT/US2018/044337 patent/WO2019027881A1/fr unknown
- 2018-07-30 IL IL272023A patent/IL272023B2/en unknown
- 2018-07-30 AU AU2018309667A patent/AU2018309667B2/en active Active
- 2018-07-30 EP EP18756041.2A patent/EP3661518B1/fr active Active
- 2018-07-30 MD MDE20200610T patent/MD3661518T2/ro unknown
- 2018-07-30 HR HRP20241359TT patent/HRP20241359T1/hr unknown
- 2018-07-31 TW TW107126573A patent/TW201909896A/zh unknown
-
2019
- 2019-12-09 CL CL2019003598A patent/CL2019003598A1/es unknown
- 2019-12-19 ZA ZA2019/08495A patent/ZA201908495B/en unknown
-
2022
- 2022-08-26 JP JP2022134792A patent/JP7529952B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| MA43817B1 (fr) | Méthodes de traitement de la dépression à l'aide d'antagonistes de récepteurs de l'orexine-2 | |
| NI201100147A (es) | Métodos para tratar infartos agudos de miocardio y trastornos relacionados. | |
| AR109103A1 (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert | |
| EA202191079A1 (ru) | Способы лечения синдрома ретта с применением фенфлурамина | |
| JP2017506624A5 (fr) | ||
| PE20150161A1 (es) | Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple | |
| MA43828A (fr) | Agents thérapeutiques pour maladies neurodégénératives | |
| JP2019530706A5 (fr) | ||
| Gittelman et al. | The POTENT II randomised trial: efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction | |
| PH12019502651A1 (en) | Use of vibegron to treat overactive bladder | |
| MA39294B1 (fr) | Polythérapie contre le cancer | |
| EP4233850A3 (fr) | Formulations de capsules | |
| JP2016510343A5 (fr) | ||
| MA39447B1 (fr) | Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine | |
| JP2016505050A5 (fr) | ||
| EA202193190A1 (ru) | Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов | |
| MA49754B1 (fr) | Méthodes de traitement de symptômes de gastroparésie au moyen de velusetrag | |
| MA39448B1 (fr) | (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical | |
| MA45202B1 (fr) | Composition pharmaceutique comprenant un antagoniste du récepteur minéralocorticoïde et son utilisation | |
| MX2022006083A (es) | Metodos para tratar afecciones relacionadas con el receptor s1p1. | |
| MA33455B1 (fr) | Otamixaban pour le traitement de patients atteints d'infarctus du myocarde sans élévation du st ages et insuffisants renaux | |
| ZA202200331B (en) | Naltrexone formulation | |
| MX2021007324A (es) | Terapia oral con acido 6,8-bis-benciltio-octanoico. |